
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc has recently improved its financial position through successful equity financings and option exercises, leading to increased financing income to $284K for the quarter and $611K year-to-date, compared to prior figures. The company's strategic expansion of its commercial and production capabilities, alongside positive feedback from healthcare providers regarding the LIBERTY Endovascular Robotic System, positions it well for a successful market rollout anticipated in 2Q26. Additionally, the partnership with a third-party logistics provider enhances operational readiness, suggesting strong potential for growth and justifying a premium market valuation as the company prepares for significant upcoming product launches.
Bears say
Microbot Medical Inc. faces significant risks that contribute to a negative outlook on its stock, primarily due to potential delays in the commercialization of its LIBERTY Endovascular Robotic System and unsuccessful expansion into cardio and neuro applications. The company's lack of profitability in the near term, compounded by reimbursement challenges and slow adoption rates, raises concerns about its financial sustainability. Additionally, setbacks in securing international regulatory approvals and insufficient data from randomized controlled trials further exacerbate the uncertainties surrounding its market potential.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares